This is a preprint.
Protein-primed DNA homopolymer synthesis by an antiviral reverse transcriptase
- PMID: 40196691
- PMCID: PMC11974808
- DOI: 10.1101/2025.03.24.645077
Protein-primed DNA homopolymer synthesis by an antiviral reverse transcriptase
Update in
-
Protein-primed homopolymer synthesis by an antiviral reverse transcriptase.Nature. 2025 Jul;643(8074):1352-1362. doi: 10.1038/s41586-025-09179-5. Epub 2025 May 28. Nature. 2025. PMID: 40436039 Free PMC article.
Abstract
Bacteria defend themselves from viral predation using diverse immune systems, many of which sense and target foreign DNA for degradation1. Defense-associated reverse transcriptase (DRT) systems provide an intriguing counterpoint to this strategy by leveraging DNA synthesis instead2,3. We and others recently showed that DRT2 systems use an RNA template to assemble a de novo gene, leading to expression of an antiviral effector protein, Neo4,5. It remains unknown whether similar mechanisms of defense are employed by other DRT families. Focusing on DRT9, here we uncover an unprecedented mechanism of DNA homopolymer synthesis, in which viral infection triggers polydeoxyadenylate (poly-dA) accumulation in the cell to drive abortive infection and population-level immunity. Cryo-EM structures reveal how a conserved noncoding RNA serves as both a structural scaffold and reverse transcription template to direct hexameric complex assembly and RNA-templated poly-dA synthesis. Remarkably, biochemical and functional experiments identify conserved tyrosine residues within the reverse transcriptase itself that prime DNA synthesis, leading to the formation of high-molecular weight protein-DNA covalent adducts. Synthesis of poly-dA in vivo is regulated by the competing activities of phage-encoded triggers and host-encoded silencers of DRT9. Collectively, our work unveils a novel nucleic acid-driven defense system that expands the paradigm of bacterial immunity and broadens the known functions of reverse transcriptases.
Conflict of interest statement
COMPETING INTERESTS S.H.S. is a co-founder and scientific advisor to Dahlia Biosciences, a scientific advisor to CrisprBits and Prime Medicine, and an equity holder in Dahlia Biosciences and CrisprBits. B.W. is the founder of SurGene LLC and inventor on patent applications related to CRISPR–Cas systems and applications thereof. The remaining authors declare no competing interests.
Figures






References
-
- Georjon H. & Bernheim A. The highly diverse antiphage defence systems of bacteria. Nat. Rev. Microbiol. 21, 686–700 (2023). - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous